Pricing
  1. JP-listed companies
  2. RIBOMIC Inc.
  3. Financials
  4. Total cash & short-term investments

RIBOMIC Inc.【JP:4591】

Market cap
¥4.4B
P/E ratio
-3.8x
Ribomics develops next-generation aptamer drugs using its proprietary RiboART System to treat unmet medical needs like achondroplasia and eye diseases.
SummaryFinancialsDividendsHistoryOwnershipWorkforce
Period EndTotal cash & short-term investments (Million JPY)YoY (%)
Mar 31, 20253,037-10.67%
Mar 31, 20243,400-21.40%
Mar 31, 20234,325-8.01%
Mar 31, 20224,702-19.46%
Mar 31, 20215,838+191.65%
Mar 31, 20202,002-17.08%
Mar 31, 20192,414+10.69%
Mar 31, 20182,181-8.51%
Mar 31, 20172,384-22.10%
Mar 31, 20163,060-8.30%
Mar 31, 20153,337

Income Statement

RevenueRevenue growth (%)Cost of revenueGross profitGross margin (%)Research & developmentSelling, general & administrativeOperating margin (%)Operating expenses Operating income Income before tax Pretax margin (%)Provision for income taxesEffective tax rate (%)Net income Net income margin (%)Earnings per shareDiluted EPSDividend payout ratio (%)Dividend per shareEBITDAEBITDA margin (%)

Balance Sheet

Cash and cash equivalents Marketable securities, current Total cash & short-term investmentsAccounts receivable, netInventoriesTotal current assetsProperty, plant and equipment, netMarketable securities, non-current Total non-current assetsTotal assets Accounts payableShort-term debtLong-term debt, current Total current liabilitiesLong-term debt, non-current Total non-current liabilitiesTotal liabilities Common stock and paid-in capital Retained earningsStockholders' equityTotal debtNet debtD/E ratio (%)Working capital

Cash Flow

Depreciation & amortizationStock-based compensationCash from operations Capital expendituresCash from investing Payments for dividends Repurchases of common stockProceeds from issuance of term debt, netRepayments of term debtCash from financing Free cash flowFCF margin (%)